ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
Results of Operations and Financial Condition.
ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Results of Operations and Financial Condition
On August 3, 2017, ARCA biopharma, Inc. (“ARCA”) issued a press release reporting financial results for the quarter ended June30,2017.
The press release is attached hereto as Exhibit99.1, which is furnished under Item 2.02 of this report and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Section 9 — Financial Statements and Exhibits
Item 2.02. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press Release titled “ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update” dated August 3, 2017. |
ARCA biopharma, Inc. ExhibitEX-99.1 2 abio-ex991_6.htm EX-99.1 abio-ex991_6.htm Exhibit 99.1 ARCA Biopharma announces SECOND quarter 2017 financial results and provides business update ————————————————————————————————– Outcome of GENETIC-AF Data and Safety Monitoring Board Phase 2B Interim Efficacy Analysis and Recommendation Anticipated in August 2017 Westminster,…To view the full exhibit click here
About ARCA biopharma, Inc. (NASDAQ:ABIO)
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
